18F-FDG PET/CT Imaging Improves Diagnostic Process for Fever of Unknown Origin

Diagnostic Utility of 18F-FDG PET/CT in Fever of Unknown Origin

In a cohort of more than 900 patients, the use of molecular imaging directly influenced clinical management in nearly 75% of cases. These influences included the introduction of new therapies, the modulation of existing treatments, or the recommendation of specific invasive procedures. Researchers noted that this diagnostic approach contributed to improved patient outcomes, increased safety, and reduced health care costs.

Current Diagnostic Challenges and Procedures

There is currently no established diagnostic gold standard for FUO. Typically, investigations are tailored to a patient’s specific clinical features and history. The diagnostic process traditionally begins with a comprehensive physical examination, medical history, and first-line laboratory testing, such as complete blood counts, electrolyte panels, chest X-rays, and inflammatory markers like C-reactive protein (CRP).

When these initial steps fail to identify a cause, advanced imaging techniques are utilized as second-line testing. While 18F-FDG PET/CT is predominantly recognized for its application in oncology, it has demonstrated significant utility in identifying inflammatory and infectious diseases (Medicalxpress).

Predictive Markers for Imaging Success

The study identified several parameters associated with positive 18F-FDG PET/CT results. Researchers found that a positive scan is more likely in patients exhibiting:

• High C-reactive protein (CRP) levels
• A high neutrophil-to-lymphocyte ratio
• The presence of fever at the time of the PET scan
• A short duration of prior antibiotic therapy

In the broader study cohort, 549 patients yielded positive PET/CT results, while 380 patients had negative results. The final diagnosis for each patient was established through a combination of laboratory, histopathologic, and imaging examinations, supported by at least six months of clinical follow-up data (Medicalxpress).

Clinical Standards and Regulatory Requirements

The use of nuclear medicine imaging for FUO is guided by appropriate use criteria (AUC) established by an autonomous expert work group, which included representatives from the Society of Nuclear Medicine and Molecular Imaging (SNMMI), the Infectious Diseases Society of America, and the American College of Nuclear Medicine (Snmjournals).

This guidance ensures that advanced imaging is integrated into the diagnostic workflow in accordance with the Protecting Access to Medicare Act of 2014. This legislation requires referring physicians to consult AUC via a clinical decision support mechanism before ordering advanced diagnostic services. The work group’s findings emphasize that recommendations for FUO also apply to inflammation of unknown origin (IUO), as the criteria and common etiologies for both entities are similar.

Application in Critical Care Settings

The role of 18F-FDG PET/CT extends to intensive care unit (ICU) patients, where persistent illness despite initial diagnostic efforts remains a critical issue. According to research published in Annals of Intensive Care (Auntminnie), the imaging technique helped detect an infectious or inflammatory focus in 91% of ICU patients studied. Notably, 72% of these findings were previously unknown.

For these critically ill patients, who have often undergone multiple prior diagnostic procedures such as standard X-rays and CT scans, the PET/CT scan serves as a vital tool for uncovering hidden sources of infection. Authors of the study suggest that future research should focus on identifying specific biomarkers that can predict which patients will derive the highest diagnostic yield from PET/CT imaging.